arteries, fibrotic changes that reduce compliance and promote renal damage in hypertension, and as a focus for inflammatory cell accumulation in development of medial dissections and aneurysms. [6] [7] [8] [9] In smaller vessels, the adventitia and associated perivascular cells are important signaling niches for resident progenitor cells in skeletal muscle, 10 kidney, 11 and bone marrow hematopoietic stem cells. 12 The perivascular niche is also a residence site for dormant cancer cells with metastatic potential. 13 Thus, factors governing the cell composition of the adventitia are important to identify for the health and maintenance of blood vessels and the tissues and stem cell populations they support.
In recent years, reports demonstrating the existence of resident cardiovascular progenitor cells have had profound effects on our understanding of cardiovascular biology and tissue regeneration. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Emerging data suggest that several distinct progenitor populations with the capacity to differentiate into endothelial cells, SMCs, fibroblasts, and macrophages reside in a specialized niche in the adventitia at the media-adventitia border. Hu et al 2 described a population of vascular progenitor cells in the aortic root adventitia of ApoE −/− mice that express the progenitor markers Sca1 and CD34 and differentiate to vascular SMCs in vitro (adventitial sca1-positive progenitor cell [AdvSca1] progenitors). Our group showed similar cell clusters in an adventitial domain of sonic hedgehog signaling and, although SMC marker negative, were found to express transcription factors known to activate SMC markers (eg, serum response factor [SRF] and myocardin). 4 They also express high levels of SRF corepressors (eg, Klf4), suggesting that AdvSca1(+) progenitors are specified for the SMC fate, but transcriptional repression maintains their progenitor phenotype. AdvSca1 progenitors were shown to have the potential to self-renew or to differentiate in vitro into SMCs, endothelial cells, osteoblasts, chondrocytes, or adipocytes. 4, 24 These cells are not unique to murine vessels as adventitialderived CD34(+) progenitor cells have also been isolated from human vessels. 14, 25 In addition, an intriguing finding was the existence of local, resident AdvSca1 myeloid progenitors with hematopoietic potential that reside in a similar adventitial niche. 5, 26 The presence of resident vascular progenitor cells has significant implications for their potential therapeutic use in the treatment of vascular diseases and regenerative medicine. Although accumulating evidence supports their existence, many important questions remain unanswered. Several groups 2, 5, 24 demonstrated that these cells do not originate from bone marrow, and our previous findings 4 demonstrated that adventitial progenitors do not arise from cardiac neural crest. Therefore, the origin of AdvSca1 progenitor cells remains unclear. In addition, the degree of heterogeneity of AdvSca1
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• Differentiated SMCs in the outer media migrate into the inner adventitia and lose expression of SMC markers, gain expression of progenitor cell markers, and contribute to a subpopulation of AdvSca1 progenitor cells.
• SMC-derived AdvSca1 cells can differentiate to mural cells, macrophage-like cells, and endothelial-like cells within Matrigel implants in vivo. They can also give rise to adipocytes and chondrocytes under defined in vitro conditions at lower frequencies.
• Formation and maintenance of AdvSca1 cells from SMCs is dependent on induction of the pluripotency-associated transcription factor, Kruppel-like factor 4.
The vascular adventitia is a complex layer of the vessel wall containing populations of leukocytes, microvessels, and resident progenitor cells that collectively maintain the artery wall and respond robustly to arterial injury. Factors governing the cell composition of the adventitia are expected to contribute to the health and maintenance of blood vessels and the tissues and stem cell populations they support. Identification and characterization of resident vascular progenitor cells might have significant therapeutic implications in vascular diseases and regenerative medicine. We show that differentiated SMCs migrate from the arterial media into the adventitia and revert to multipotent vascular progenitor cells through a physiological reprogramming-like process. Depending on environmental cues, SMC-derived progenitor cells may adopt cell fates resembling tissue resident macrophages, mural cells, endothelial cells, adipocytes, and osteoblasts. SMC reprogramming is dependent on induction of the transcription factor, Kruppel-like factor 4. Moving forward, identification of additional factors regulating the SMC-to-progenitor cell transition in vivo is expected to broaden our understanding of the multiple roles SMCs play in vascular homeostasis and disease.
Manipulations of these cells in situ might have therapeutic applications in settings such as atherosclerosis/restenosis, aneurysm, ischemia, and tumor angiogenesis.
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progenitors and the mechanism underlying the maintenance of the AdvSca1 progenitor cell phenotype are also unclear. Vascular SMCs are specialized cells that express high levels of SMC-specific proteins, such as smooth muscle myosin heavy chain (Myh11/SMMHC) and smooth muscle-α-actin (Acta2/αSMC). 27 Under pathological conditions, such as atherosclerosis and restenosis, however, SMCs are capable of undergoing phenotypic and functional changes resulting in a proliferative, inflammatory phenotype, characterized by decreased expression of SMC contractile proteins and increased production of proinflammatory cytokines. As a result, mature SMCs are major contributors to pathological neointima formation. [28] [29] [30] [31] [32] Our previous report using a highly specific SMC fate-mapping approach in the setting of restenosis demonstrated that the majority of proliferating intimal cells derive from mature SMCs. 33 Remarkably, we also consistently detected reporter-positive, but SMC marker-negative, SMC-derived cells in the arterial adventitia, suggesting that mature SMCs contribute to both intimal and adventitial remodeling. In addition, recent reports demonstrated that a high percentage of SMCs in atherosclerotic lesions lack detectable expression of conventional SMC markers but exhibit a macrophage-like phenotype. 31, 34, 35 These findings suggest that SMCs exhibit an even greater degree of plasticity than previously recognized. In light of our findings that SMCs contribute to adventitial remodeling and because the origin of AdvSca1 progenitor cells remains unknown, we sought to determine whether mature SMCs contribute to the vascular progenitor pool. Using fate-mapping and lineage-tracing approaches, in this report, we demonstrate that a distinct subpopulation of AdvSca1 progenitors derive from differentiated SMCs that undergo a reprogramming-like process in situ to generate multipotent progenitor cells. In addition, we show here that the pluripotency-associated transcription factor, Klf4, regulates the generation of SMC-derived AdvSca1 cells and is essential for the maintenance of the AdvSca1 progenitor cell phenotype.
Methods Mice
Myh11-CreER
T2 transgenic mice and Rosa26-LacZ or Rosa26-YFP reporter mice were bred to generate tamoxifen-inducible SMC-specific β-galactosidase-or yellow fluorescent protein (YFP)-expressing mice (Myh11-CreERT-βGal/YFP). To activate Cre (Cre recombinase), adult male mice received 1-mg IP tamoxifen injections for 5 consecutive days 8 weeks before they were euthanized. Timed pregnant female mice (Rosa26-YFP female mice bred to male Myh11-CreERT-Rosa26-YFP mice) received 1-mg IP tamoxifen injections at e15 and e16 to label developing embryos. SM22α-Cre transgenic mice were bred to Rosa26-YFP to generate SMC-specific YFP-expressing mice (SM22α-Cre-YFP). For in vivo Matrigel plug assays, SMC-derived AdvSca1 cells were isolated as described below, resuspended in 700 µL Matrigel plus 100 ng/mL VEGF (vascular endothelial growth factor) and 100 ng/mL FGF2 (fibroblast growth factor-2), and injected subcutaneously into wild-type (WT) C57BL/6 recipients. Plugs were harvested 14 days postinjection, fixed in 4% buffered paraformaldehyde, and embedded in optimal cutting temperature compound for immunofluorescent staining. To induce vascular injury, mice were subjected to wire-induced femoral artery injury or carotid artery ligation injury, as previously demonstrated. 33, 36 Four weeks after femoral artery injury or 3 days after carotid artery ligation injury, uninjured and injured arteries were harvested, perfusion fixed in 4% buffered paraformaldehyde, and embedded in optimal cutting temperature compound for immunofluorescent staining. SM22α-CreKI transgenic mice (Tagln
tm2(cre)Yec
; JAX stock 006878) were bred to Klf4 floxed mice and Rosa26-YFP mice to generate SMC-specific YFP-expressing Klf4-deficient mice (SM22α-CreKI-YFP knockout). This alternative SMC Cre driver, in which Cre recombinase is activated late in development compared with the traditional SM22α-Cre mouse line (TagIn-Cre; JAX stock 004746), was used to generate SMC-specific Klf4 knockout mice as use of TagInCre mice resulted in embryonic lethality. Mice were maintained in the Center for Comparative Medicine, and procedures were performed under a protocol approved by the Institutional Animal Care and Use Committee at the University of Colorado Denver.
Cell Analysis
Isolated aortic arch plus left and right carotid arteries, descending aortas, and left and right femoral arteries were digested to single cells by digestion at 37 °C for 1 hour in collagenase buffer. For flow sorting, single cell suspensions were incubated with a rat anti-mouse monoclonal allophycocyanin (APC)-Sca1 antibody (eBiosciences); live cells were sorted on a MoFlo high-speed cell sorter based on Sca1-APC and endogenous YFP expression. For fluorescence-activated cell sorting analysis, single cell suspensions were stained with various combinations of rat anti-mouse monoclonal antibodies (PerCPCy5.5-Sca1, PE-Cy7-CD45, APC/e780-Ly6C, PE-Cy7-CD115, APC-CD140a, APC-CD140b, and PE-CD31; all antibodies were from eBiosciences). Flow cytometry was performed on a Galios cytometer (Becton Dickenson). Data were analyzed using Kaluza software (Beckman Coulter). To quantify AdvSca1 populations in WT versus SMC-specific Klf4 knockout mice, vessels from 8-to 10-day-old mice were individually digested to single cell suspensions, labeled with anti-APC-Sca1 antibodies, and analyzed for endogenous YFP and Sca1-APC expression. To analyze the effect of Klf4 on maintenance of the AdvSca1 progenitor cell phenotype, AdvSca1 cells were sorted based on Sca1 expression, transfected with nontargeting or Klf4-targeting siGENOME SMARTpool siRNAs (100 nm; Thermo Scientific), or transduced with an empty vector adenovirus or an adenovirus expressing Klf4 (100 multiplicity of infection; Vector Bioloabs, Malvern, PA).
Immunofluorescence, Chromatin Immunoprecipitation, and Quantitative Real-Time Polymerase Chain Reaction
Optimal cutting temperature compound-embedded tissues or fixed cells were permeabilized with MeOH followed by 0.05% Tween-20 in PBS, blocked in 3% horse serum, and sequentially incubated with specific primary and secondary antibodies. Antibodies used include monoclonal rat anti-mouse Sca1 (1:100; BD Pharmingen), monoclonal rat anti-mouse CD34 (1:50; Abcam), fluorescein isothiocyanateconjugated polyclonal goat anti-green fluorescent protein (GFP; 1:200; Abcam), Cy3-conjugated monoclonal anti-αSMA (1:2000; Sigma), monoclonal rat anti-mouse CD45 (1:100; BD Pharmingen), polyclonal rabbit anti-Klf4 (1:100; Abcam), monoclonal rat antimouse F4/80 (1:50; Abcam), polyclonal rabbit anti-αSMA (1:200; Abcam), and polyclonal rabbit anti-SMMHC (1:100; Biomedical Technologies, Inc). Sections/cells were imaged using a laser-scanning confocal microscope (LSM 780 spectral; Carl Zeiss, Thornwood, NY). Tissues were stained for β-galactosidase activity using a kit from GTS, Inc, according to the protocols provided. To quantify cell populations in uninjured compared with injured carotid arteries, total numbers of Sca1 or CD45(−) YFP(+), Sca1 or CD45(+) YFP(+), and Sca1 or CD45(+) YFP(−) adventitial cells were counted in 3 highpowered fields per vessel from n=3 uninjured and injured vessels by 2 independent investigators. Chromatin immunoprecipitation (ChIP) was performed on flow-isolated cell populations as previously described. 37 Antibodies for ChIP include anti-H3K4Me2, anti-H4-Ac (Millipore), and anti-SRF (Santa Cruz Biotechnologies). DNA was purified with QIAquick PCR purification kits (Qiagen). Real-time polymerase chain reaction with Power SYBR Green Mastermix (Life Technologies) and primers designed to flank CArG elements in the Acta2 and Myh11 promoters were used to analyze ChIP (primer sequences are available in the Online Data Supplement). Data from a minimum of 3 independent experiments were normalized to YFP+ SMCs. Quantitative real-time polymerase chain reaction was used with total RNA isolated from flow-isolated cell populations as previously described. 33 Primer sequences are available in the Online Data Supplement. β-Actin was used for normalization. To compare among individual experiments, data were normalized to YFP+ SMCs for SMC genes (αSMA, SMMHC, SM22α, and myocardin) or AdvSca1-MA cells for progenitor cell genes (Klf4, CD34, VEGF, SDF-1α, CD31, Flk1, and Flt1).
Results
Genetic Fate Mapping Reveals Adventitial SMCDerived Progenitor Cells
We previously used tamoxifen-inducible Myh11
CreERT2 transgenic mice crossed with floxed-stop Rosa reporter mice (Myh11-CreER-βGal/YFP) to fate map mature SMCs in response to vascular injury. 33 Tamoxifen given to adult mice before vascular injury genetically, permanently, and efficiently marked only Myh11/SMMHC-expressing SMCs through Cremediated reporter knock-in. Because tamoxifen was given before injury and then stopped, SMCs expressing Myh11/ SMMHC and their progeny were the only reporter-positive cells throughout the experimental period, allowing tracking of mature SMCs in response to vascular injury even if levels of Myh11/SMMHC (or other SMC markers) were no longer detectable; any non-SMC that potentially gained expression of Myh11/SMMHC after injury would not be labeled as tamoxifen was not in the system to activate Cre. Using this approach, we found that the majority of intimal Acta2/αSMA-expressing cells originate from mature SMCs 33 (Online Figure I ), establishing that neointimal SMCs derive from mature differentiated SMCs. However, similar to a recent report in the setting of atherosclerosis, 33 we also detected populations of YFP(+) SMC-derived intimal cells that expressed no detectable levels of SM markers (asterisks in Online Figure I ), suggesting that the contribution of SMCs to intimal hyperplasia is underestimated if solely using expression of conventional SMC marker proteins to identify intimal SMCs. Mice not treated with tamoxifen exhibited no genetic labeling of SMCs or adventitial cells (Online Figure II) . In addition to intimal SMCs, we made the entirely unanticipated observation that over time mature SMCs migrate to the adventitia and reside in a niche at the adventitia-media border 33 ( Figure 1A ). Adventitial SMC-derived cells have lost SMC marker expression (Figure Our previous report demonstrated that AdvSca1 progenitors appear in the adventitia of the ascending aorta and pulmonary trunk by e18.5, a developmental time point after the arterial media has acquired its complement of SMCs and has organized structured elastic lamellae. 4 Based on this, we hypothesized that SMC-derived AdvSca1 progenitors are established during the late embryonic-to-early postnatal period. To test this hypothesis, tamoxifen was administered to timedpregnant female mice at e15 and e16 to obtain restricted labeling of Myh11-expressing SMCs in embryos between e15 and e17, when all vascular beds exhibit strong Myh11/SMMHC expression and before the appearance of AdvSca1 cells. Pups were allowed to develop to 30 days postpartum, then carotid arteries plus aortic arch, descending aortas, and femoral arteries were harvested, digested into single cells, immunolabeled for Sca1, and flow sorted based on Sca1 and YFP expression (gating strategy shown in Online Figure III ). Three distinct cell populations were retrieved from each vessel: (1) Using this approach, we found that ≈8% of the total Sca1(+) cell population were YFP-positive SMC-derived cells (Online Figure IVB) . In contrast to blood vessels, AdvSca1-SM cells were not detected in peripheral blood mononuclear cells (not shown). This is consistent with our previous finding of a lack of labeled cells in bone marrow 33 and a previous report using a comparable SMC-specific labeling approach in which labeled cells were not detected in bone marrow cells or the circulation. 34 Others have used a similar in utero tamoxifen pulse to fate-map yolk sac-derived myeloid progenitors 38 and hemogenic endothelial cells, 39 albeit tamoxifen was administered at much earlier developmental time points (eg, e8.5). In contrast to these studies, on further examination in our system, although 5-day tamoxifen treatment of adult mice resulted in highly efficient labeling of medial SMCs, 33 we were unable to achieve similar labeling delivering tamoxifen in utero at these later time points (2 injections failed to efficiently label outer medial SMCs (Online Figure IVC) and >2 in utero injections consistently resulted in premature termination of pregnancy), thus precluding the ability to accurately quantify the percentage of AdvSca1 progenitors that originate from SMCs because of lack of genetic labeling. Nonetheless, using a highly selective fate-mapping approach, our data demonstrate that a population of resident AdvSca1 cells derives from mature SMCs.
To accurately quantify the percentage of AdvSca1 cells that originate from SMCs, constitutive, SMC-specific SM22α-Cre transgenic mice were bred to Rosa26-YFP mice (SM22α-Cre-YFP) to label differentiating SMCs at the time in vascular development that SM22α is induced. We previously showed that AdvSca1 cells do not express SM22α 4 Using this approach, we consistently found that a large percentage of total Sca1(+) cells in the carotid artery plus aortic arch, descending aorta, and femoral artery originate from SMCs ( Figure 2A ; Online Figure V) . By immunofluorescent staining, αSMA(−), but YFP(+)Sca1(+)CD34(+), cells were detected in the adventitia of 30-day-old SM22α-Cre-YFP mice ( Figure 2B and 2C). Consistent with in vivo staining, freshly isolated AdvSca1-SM cells from 30-day-old SM22α-Cre-YFP mice express high levels of progenitor cell markers, including Sca1, CD34, and the pluripotency-associated transcription factor, Klf4, but dim to undetectable levels of αSMA (Online Figure VI) . To further strengthen that SMCs migrate into the adventitia and to provide evidence of the late developmental timing of SMC reprogramming, we analyzed arteries from 5-day-old SM22α-Cre-YFP mice and detected Sca1(+)YFP(+) adventitial cells still expressing residual SMC markers ( Figure 2D ). Specific chromatin modifications occur selectively in SMC gene loci of SM markers (eg, Acta2/αSMA and Myh11/SMMHC) and are associated with specification of the SMC lineage during development. 40, 41 Unlike most that are lost from SMC genes in response to SMC phenotypic switching (eg, H4Ac), 1 chromatin mark in particular, H3K4 dimethylation (H3K4Me2), is retained and serves as a highly specific SMC lineage marker in both mouse and human tissues. 40, 42 As a secondary approach to demonstrate SMC origin of YFP(+)Sca1(+) AdvSca1 cells, ChIP was conducted for expression of the H3K4Me2 mark in the Myh11 and Acta2 loci of isolated YFP(+)Sca1(+) compared with YFP(−)Sca1(+) cells. Similar to SMC-rich intact aortic media (not shown), H3K4Me2 was detected on the Myh11/ SMMHC and Acta2/αSMA promoters of isolated YFP(+) mature SMCs and YFP(+)Sca1(+) AdvSca1-SM cells but not YFP(−)Sca1(+) AdvSca1-MA cells (Online Figure VIIA) .
In contrast, compared with mature YFP(+) SMCs, expression of the SMC differentiation-associated H4Ac chromatin mark 40 was undetectable in YFP(+)Sca1(+) AdvSca1-SM cells (Online Figure VIIB left; Myh11 shown) . Binding of the transcription factor, SRF, to CArG boxes of SM gene promoters is essential for promoting the SMC differentiation program. 40 Loss of the SMC differentiation H4Ac chromatin mark was associated with undetectable SRF binding to SM gene promoters in YFP(+)Sca1(+) AdvSca1-SM cells (Online Figure VIIB right; Myh11 shown) . Collectively, using 2 independent genetic fate-mapping systems combined with a SMC lineage histone mark, we established 
Differentiated SMCs Generate Phenotypically Distinct Subpopulations of AdvSca1 Cells
We used quantitative real-time polymerase chain reaction to further characterize individual cell populations. Mature SMCs, AdvSca1-SM progenitors, and AdvSca1-MA progenitors were isolated by flow sorting as described above. Compared with mature YFP(+)Sca1(−) SMCs, expression of the SMC-specific mRNAs, Myh11/SMMHC, Acta2/αSMA, TagIn/SM22α, and Mycdn/myocardin was undetectable in both AdvSca1-SM and AdvSca1-MA progenitors ( Figure 3A) . No difference in expression of SRF was detected among the cell populations ( Figure 3A) . However, combined with loss of SRF binding to SM gene promoters by ChIP analysis (Online Figure VII) , these results suggest that the SMC differentiation program is repressed in AdvSca1-SM cells. In contrast to SM-specific genes, Klf4, the progenitor cell marker CD34, and progenitor cell-associated cytokines, VEGF and SDF-1α, were highly expressed in both populations of AdvSca1 cells compared with mature SMCs (Figure 3B ). Finally, CD31, Flk-1, and Flt-1, commonly associated with endothelial/monocyte progenitor cells, were selectively expressed by AdvSca1-MA, but not by AdvSca1-SM, progenitor cells ( Figure 3C ), suggesting that 2 distinct populations of AdvSca1 progenitor cells reside in the vessel wall.
We used flow cytometry to further immunophenotypically characterize these subpopulations. Two recent reports identified a population of nonhematopoietic-derived resident adventitial Sca1(+)CD45(+) macrophage progenitor cells. Table I ). Although the majority of Sca1(+) CD45(−) and Sca1(+)CD45(+) AdvSca1-MA progenitors also expressed Ly6C, only approximately half of Sca1(+) CD45(−) (54.6%) and Sca1(+)CD45(+) (56.1%) AdvSca1-SM progenitors expressed Ly6C (Figure 4C and 4F; Online Table I ). Ly6C(+) cells within the YFP(+)Sca1(+) and YFP(−) Sca1(+) populations coexpressed CD115, also a common monocyte progenitor marker ( Figure 4D, circled populations) . Expression of the platelet-derived growth factor receptors PDGF-Rβ/CD140b and PDGF-Rα/CD140a has been implicated in regulating a variety of progenitor cells and, in particular, specification of a SMC fate. CD31 is a cell surface marker Table I ; CD140b shown). All non-SMC Sca1(+) CD45(+) cells were negative for CD140b, CD140a, and CD31 ( Figure 4F ; Online Table I ), whereas SMC-derived Sca1(+) CD45(+) cells either expressed Ly6C and CD115 or CD140b and CD140a; none expressed CD31 ( Figure 4F ; Online Table  I To determine whether AdvSca1-SM cells possess multipotency potential capable of differentiating into other cell lineages, in vivo Matrigel plug angiogenesis assays were performed. AdvSca1-SM cells were recovered from SM22α-Cre-YFP mice, resuspended in Matrigel plus growth factors, subcutaneously injected into syngeneic WT mice, and plugs examined 14 days postimplantation for SMC-, macrophage-, and endothelial cell-specific markers (Myh11/SMMHC, F4/80, and von Willebrand factor, respectively). Analysis of YFP(+) cells demonstrated that AdvSca1-SM cells contribute to perivascular cells of functioning neovessels within Matrigel Figure XC) . In vitro differentiation assays demonstrated the ability of SMC-derived AdvSca1 cells to also differentiate into adipocytes and chondrocytes (Online Figure  XI) , thereby supporting the concept that AdvSca1-SM cells exhibit a multipotent progenitor cell phenotype. Collectively, these data suggest that differentiated SMCs can generate distinct subpopulations of multipotent progenitor cells that reside in the vascular adventitia.
AdvSca1-SM Cells Expand in Number in Response to Vascular Injury
Although the predominant focus of the vascular response to injury has been on neointima formation and vessel occlusion, previous reports have also demonstrated early activation and expansion of adventitial cells after injury. [43] [44] [45] [46] To determine whether AdvSca1-SM cells contribute to adventitial cell expansion early after vascular injury, carotid artery ligation injuries were performed on 2-month-old SM22α-Cre-YFP mice. Compared with uninjured contralateral controls (Online Figure Figure 6B and 6E) . Similarly, there were increased numbers of CD45+YFP+ and CD45-YFP+ adventitial cells in response to injury. Although rare in uninjured vessels, SMC-derived CD45+ adventitial cells increased in response to injury; the majority of CD45+ adventitial cells, however, were YFPnon-SMC-derived cells ( Figure 6C, 6D, and 6F ). These data are consistent with the concept that resident vascular progenitor cells, and in particular SMC-derived AdvSca1 cells, are activated early and are the dominant source of adventitial remodeling in response to vascular injury.
SMC Generation of AdvSca1-SM Cells Is Dependent on Induction of Klf4
Although many somatic cells, including SMCs, have been successfully reprogrammed in vitro to induced pluripotent stem cells using exogenous approaches, 47 endogenous mechanisms directing reprogramming are largely undefined. Klf4, a Kruppel-like transcription factor member, is not expressed in differentiated SMCs (Figure 3 ), but its induction contributes to SMC phenotypic switching. 48 Klf4 has been shown to be 1 of 4 genes necessary for in vitro induced pluripotent stem cell generation, underscoring its importance in maintenance of a progenitor cell phenotype. 49 Because Klf4 was highly expressed by AdvSca1-SM cells ( Figure  3 ; Online Figure VI) , we examined its role in SMC generation of AdvSca1-SM cells. To determine whether induction of Klf4 in differentiated SMCs was required in vivo, aortas from 8-to 10-day-old WT and SMC-specific Klf4-deficient mice (SM22α-CreKI-YFP Klf4 SM-knockout) were examined for the presence of AdvSca1 cells. We found abundant numbers of adventitial Sca1+ cells in WT mice ( Figure 7A ). In contrast, adventitial Sca1+ cells were barely detectable in aortae from SM22α-CreKI-YFP Klf4 SM-knockout mice ( Figure 7B ). Fluorescence-activated cell sorting analysis was used to quantify AdvSca1-SM and AdvSca1-MA cells in WT and Klf4 SM-knockout mice. No difference in the numbers of AdvSca1-MA cells was observed, as anticipated because Klf4 was not deleted from non-SMC-derived cells ( Figure 7D ). Compared with WT mice, however, decreased numbers of AdvSca1-SM cells was confirmed in carotid arteries plus aortic arch and descending aortae of Klf4 SMknockout mice ( Figure 7C ), supporting the concept that Klf4 induction is necessary for SMCs to generate progenitor cells. Unfortunately, because of premature death of SM22α-CreKI-YFP Klf4 SM-knockout mice by 4 weeks of age 50 (M.C.M. Weiser-Evans et al, unpublished data, 2014), we were unable to demonstrate the biological importance of Klf4 in the expansion of AdvSca1-SM cells after vascular injury. To test whether Klf4 is sufficient to promote a progenitor cell phenotype as defined by expression of progenitor cell markers and repression of SM genes, cultured SMCs were transduced with adenoviruses expressing GFP (control) or Klf4-GFP. By fluorescence-activated cell sorting analysis, we observed ≈50% transduction efficiency (Online Figure XIIIA) . Compared with GFP-transduced SMCs, Klf4-transduced SMCs expressed increased levels of cell surface Sca1 and CD34 (Online Figure XIIIB and XIIIC) . This was associated with downregulation of SMC-specific markers at the level of mRNA and protein (Online Figure XIIIC and XIIID) .
We previously demonstrated that Klf4 is downregulated as AdvSca1 cells differentiate in culture and acquire SMC markers. 4 On the basis of its known function as a corepressor of SRF-dependent SMC gene transcription and as a regulator of self-renewal in embryonic stem cells, we sought to determine whether Klf4 is critical for maintenance of a progenitor cell phenotype. We used in vitro approaches to silence Klf4 using control nontargeting or Klf4-specific siRNAs or overexpress Klf4 using adenoviruses expressing empty vector (control) or wild-type Klf4. Compared with control siRNA, Klf4 knockdown decreased Sca1 mRNA expression (Online Figure XIVA) and reduced the number of Sca1-positive cells, as evaluated by immunofluorescence staining ( Figure 8A and 8B, left). This was associated with a trend toward an increased fraction of cells exhibiting αSMA-positive contractile filaments ( Figure 8A and 8B, right) , suggesting that loss of Klf4 accelerates differentiation of AdvSca1 cells toward a SMC fate. In contrast to Klf4 silencing, adenoviral-mediated overexpression of Klf4 resulted in increased Sca1 expression and decreased αSMA expression (Online Figure XIVB) . This was associated with increased numbers of Sca1-positive cells ( Figure 8C and 8D, left) and blocked the differentiation of AdvSca1 cells to SMCs, as measured by decreased fraction of cells exhibiting αSMA-positive contractile filaments ( Figure 8C and 8D, right) . Collectively, these data are consistent with an essential role for Klf4 in SMC reprogramming, similar to a recent report, 31 and in the maintenance of the AdvSca1 progenitor phenotype. 
Discussion
In previous experiments to determine the fate of medial SMCs in injured arteries, we made the entirely unexpected observation that some mature SMCs migrate from the media into the adventitia and become SMC marker negative. 33 In this report, using 2 independent SMC genetic fate-mapping systems combined with a SMC lineage-specific chromatin mark, we demonstrate that SMCs moving into the adventitia gain expression of progenitor cell markers (Sca1, CD34, and Klf4) and become residents within the adventitial progenitor niche that we and others have described. 2, 4, 5 We propose that this phenomenon is a type of in situ SMC reprogramming with the evidence to support this as follows: (1) no detectable SMC differentiation marker expression by AdvSca1-SM cells, (2) no detectable binding of SRF to CArG elements in SMC marker gene promoter regions in these cells, (3) loss of the H4Ac differentiation-associated mark on SMC promoter CArG elements by AdvSca1-SM cells, but (4) retention of the H3K4Me2 SMC lineage mark, (5) gain of expression of functional progenitor marker genes by AdvSca1-SM cells, and (6) gain of multipotential fate capabilities as defined by differentiation in vivo into SMCs, macrophages, and endothelial cells. Further study showed that SMC-derived progenitor cells reside in the adventitia of aortic arch and carotid arteries, descending aorta, and femoral arteries, each from distinct embryonic lineages, in numbers representing ≈60%, 40%, and 30%, respectively, of the total adventitial Sca1+ progenitor cell population of these vessels. Taken together, our data suggest the novel possibility that during vascular development differentiated SMCs migrate from the outer media into the inner adventitia where they become reprogrammed to a progenitor-like state. Because formation of AdvSca1-SM cells was observed in adult mice after treatment with tamoxifen, this would also suggest that SMC reprogramming is a continual process likely serving as a mechanism to replace resident vascular progenitor cells. This activity would be similar, in principle, to the reversion of mature differentiated cells to fate-restricted progenitor cells in regeneration of tracheal cell types after lung injury 51 and stomach crypt cells in response to stem cell ablation. 52 An important difference and the novel aspect of our findings, however, is that our data support the concept that formation of AdvSca1-SM cells from mature SMCs is a normal physiological process, in contrast to these previous studies in which differentiated cells revert to progenitor cells only in the setting of experimental tissue injury or stem cell ablation. We are aware that Myh11/SMMHC can sometimes be expressed by microvascular pericytes and that some myeloid and myofibroblastic cells express Acta2/αSMA and Tagln/SM22α (but not Myh11). At this time, we cannot rule out the possibility that some of the AdvSca1-SM cells we identify here may have an origin from adventitial cells. However, vasa vasorum microvessels are sparse in normal murine adventitia and a substantial origin of AdvSca1-SM cells from these alternate sources seems unlikely.
Although remodeling of the adventitia has been known to occur after many forms of vascular injury, it is widely assumed that medial SMCs do not directly participate in this response. This is likely because of the vast majority of studies in the literature that identify SMCs in injured arteries by their expression of conventional SM marker proteins (eg, Acta2/αSMA, Myh11/SMMHC). By those criteria, intimal SMCs, many plaque macrophages, 31, 34 and AdvSca1-SM cells, which lose expression of these markers, would not be recognized as SMC derived. Recent advances in SMC fate-mapping systems that permanently mark mature SMCs has allowed reliable identification of these cells as SMC-derived even if they lose all characteristics of SMCs. Using these systems, our data (Online Figure I) and recent reports by others 31, 34 have conclusively demonstrated that the percentage of SMCs contributing to intimal lesion formation and atherosclerosis is much greater than previously estimated from expression of traditional SMC markers. Although the mechanisms regulating SMC migration into the adventitia remain unclear, it is well known that breaks in the internal elastic lamina facilitate migration of SMCs into the intima. We assert that it would not be completely unexpected that breaks in the external elastic lamina, as observed during vascular development and after injury to the vessel wall, would result in a similar movement of SMCs into the adventitia. Our ongoing studies are addressing this possibility in more detail.
From their earliest description, it was evident that the AdvSca1-positive cell population in the aortic adventitia was heterogeneous. For example, Hu et al 2 reported that Sca1-positive cells isolated from the aortic root adventitia of adult ApoE −/− mice contained ≈60% fibroblastic cells, ≈20% epithelioid cells, and occasional adipocyte-like cells. Passman et al 4 and Gräbner et al 6 found that ≈50% of freshly isolated aortic AdvSca1 cells from WT C57Bl/6 mice lost Sca1 expression and differentiated into SMC marker-positive cells over 8 days ex vivo, whereas ≈25% proliferated as Sca1-positive cells without SMC differentiation, and the remaining 25% lost expression of Sca1 but did not acquire detectable levels of SMC marker expression. Psaltis et al 5 found that aortic cells isolated from WT C57Bl/6 mice exhibited hematopoietic colony-forming activity predominantly for progenitors expressing a macrophage fate. Further study showed that coexpression of Sca1 and CD45 in the adventitia marked the CFU-GM (colony-forming unit-granulocyte, monocyte) progenitor cells, and these Sca1 + /CD45 + cells comprised ≈36% of the total aortic Sca1-positive cell population. 21 The remaining Sca1 + /CD45 − cell population was shown in previous studies to possess SMC differentiation potential without hematopoietic colony-forming activity. 2, 4 Our results reported in the present study confirm and extend this previous work, supporting the concept that the aortic adventitia contains at least 2 types of AdvSca1 progenitor cells. On the basis of expression of cell surface markers, our data suggest that SMC-derived AdvSca1 cells express predominantly a myogenic progenitor phenotype (AdvSca1-SM), whereas non-SMC-derived AdvSca1 cells express predominantly a macrophage progenitor cell phenotype (AdvSca1-MA). However, myogenic and macrophage progenitor cell phenotypes were observed within subpopulations of both the AdvSca1-SM and AdvSca1-MA populations, supporting the likelihood of multipotent fate decisions. Indeed, our in vivo Matrigel plug assays and in vitro differentiation assays demonstrated the ability of AdvSca1-SM cells to differentiate into SMCs, macrophages, endothelial-like cells, adipocytes, and chondrocytes, further supporting the multipotency of these cells.
Induction of pluripotent stem cells from somatic cells can be accomplished through forced overexpression of the transcription factors, Oct-4, Sox2, Klf4, and c-Myc. 49 Our current and previous 4 results together with our unpublished RNA-Seq data demonstrate high expression levels of Klf4 and Myc/cMyc, but not POU5F1/Oct4 or Sox2, in both populations of AdvSca1 cells, further suggesting that these cells possess a fate-restricted multipotent, but not pluripotent, phenotype. This would be similar to the detection of fate-restricted progenitor cells during regeneration of axolotl limb, 53 zebrafish fin, 54 mouse digit tip, 55, 56 and both zebrafish 57 and neonatal mouse 58 hearts after apex amputation injury. Further, our finding that the AdvSca1-SM subset arises predominantly from pre-existing SMCs offers an explanation for the previously puzzling observation that despite being SMC marker-negative, AdvSca1 cells express a transcription factor profile typically found in mature SMCs. 4 Our findings suggest little contribution of AdvSca1-SM cells to the previously identified CFU-M subset. 5, 26 However, our findings suggest that AdvSca1-SM CD45 + cells contribute to the adventitial myeloid cell population, which is consistent with differentiation of AdvSca1-SM cells into macrophages as observed in in vivo Matrigel plug assays, and to expansion of adventitial CD45 + cells after vascular injury.
The adventitia is a complex layer of the vessel wall than previously thought that responds rapidly and robustly to many forms of arterial injury. 17 Previous studies point to the adventitial fibroblast as the main responders to vessel injury. For instance, Shi et al 43 and Scott et al 44 reported that adventitial cells, referred to as fibroblasts, proliferated earlier and to a greater extent than medial SMCs in response to balloon arterial injury. Our data demonstrate that AdvSca1-SM, in particular, are robustly activated and expand considerably in numbers early after arterial injury. Mobilization of AdvSca1-SM cells might participate in medial repair by differentiating into medial SMCs, and in neointimal formation. We propose that AdvSca1-SM progenitor cells may also play major roles during injury-mediated adventitial remodeling. In support of this model, and in agreement with our data, a recent report demonstrates that AdvSca1 cells are major sources of angiotensin II-induced adventitial fibrosis, leading to artery wall stiffening and hypertension. 59 Similarly, using the mdx mouse model of Duchenne muscular dystrophy, Ieronimakis et al 60 found that the major collagen-producing cell type associated with late-onset cardiac fibrosis was the coronary AdvSca1 cell. Ongoing studies using fate-mapping approaches to selectively label SMC-derived AdvSca1-SM cells are addressing these possibilities.
The pluripotency-associated transcription factor, Klf4, is also well known to regulate SMC phenotypic changes, and multiple lines of evidence support an important role for Klf4 in vascular disease progression. 31, 48 Using in vivo and in vitro approaches, our studies establish that SMC generation of AdvSca1-SM cells is dependent on induction of Klf4. In vivo targeted deletion of the Klf4 gene in SMCs resulted in selective loss of AdvSca1-SM cells, but not AdvSca1-MA cells, suggesting that failure to induce Klf4 prevents AdvSca1-SM cell generation from SMCs and establishment of this subpopulation of resident AdvSca1 cells. In support of these in vivo findings, overexpression of Klf4 in cultured SMCs promoted a progenitor cell phenotype as defined by loss of SMC differentiation markers and gain of progenitor cell markers. Unfortunately, early postnatal death of SMC-specific Klf4 SM-knockout mice precluded our ability to define the biological importance of Klf4 on expansion of AdvSca1-SM cells in response to vascular injury. We recognize that, compared with WT mice, AdvSca1-SM cell numbers decreased in SMC-specific Klf4 knockout mice by only 50%. This is likely because of the late developmental activation of Cre recombinase and thus SMC deletion of Klf4 in SM22α-CreKI compared with SM22α-Cre mice. 61 If migration into the adventitia and reprogramming occurred before Cre activation and inactivation of Klf4 in a subset of SMCs, the potential for Klf4 to be induced and promote AdvSca1-SM cell generation in this subset would remain. Finally, loss-and gainof-function studies demonstrated that Klf4 is critical for the maintenance of the AdvSca1 progenitor cell phenotype. Collectively, our data demonstrate that Klf4 is a critical regulator of AdvSca1-SM cell generation and maintenance of the resident vascular progenitor cell pool.
In summary, our findings suggest that the local environment of the inner adventitia directs or stabilizes a Klf4-dependent SMC reprogramming-like process to maintain a vascular progenitor cell pool in the artery wall. Depending on environmental cues, SMC-derived progenitor cells may express cell fates resembling tissue resident macrophages, mural cells, endothelial-like cells, adipocytes, and osteoblasts. Going forward, the identification of factors in addition to Klf4 that regulate SMC-to-progenitor cell transitions in vivo will broaden our understanding of the multiple roles SMCs play in vascular homeostasis and disease.
